Mepolizumab (Nucala)

Covered: Nucala (mepolizumab) is approved as add‑on maintenance therapy for severe eosinophilic asthma (age ≥12) and for EGPA in adults (≥18); off‑label/compendial uses are not approved. Key requirements: prescriber must be/consult an allergist, immunologist, or pulmonologist; documented blood eosinophils ≥150 cells/µL within 6 weeks; prior therapy (≥3 months ICS plus another controller for asthma or ≥4 weeks corticosteroid for EGPA); documentation of uncontrolled asthma or clinical response for reauthorization; dosing limits (100 mg q4w asthma, 300 mg q4w EGPA); initial approval 6 months, renewals 12 months.

"Add-on maintenance treatment of individuals with severe asthma having an eosinophilic phenotype"

Sign up to see full coverage criteria, indications, and limitations.